scholarly journals The paradoxical effect of glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) activation on alloreactive CD4 and CD8 T cells and the development of GVHD

2004 ◽  
Vol 10 ◽  
pp. 5
Author(s):  
S.J. Muriglan ◽  
T. Ramirez-Montagut ◽  
O. Alpdogan ◽  
T. van Huystee ◽  
J.M. Eng ◽  
...  
Blood ◽  
2003 ◽  
Vol 101 (10) ◽  
pp. 3991-3999 ◽  
Author(s):  
Masanobu Komatsu ◽  
Michele Mammolenti ◽  
Monica Jones ◽  
Roland Jurecic ◽  
Thomas J. Sayers ◽  
...  

Abstract Engraftment failure following allogeneic bone marrow (BM) transplantation is of clinical concern particularly involving T-cell–depleted inoculum and transplantations for aplastic anemia. Immune resistance by lymphoid and natural killer (NK) populations with “barrier” function is well established. Major histocompatibility complex (MHC)–identical marrow allografts were examined to investigate effector pathways in non-NK–mediated resistance. Barrier function was examined in cytotoxic normal and deficient B6 (H-2b) recipients primed to donor minor histocompatibility antigen (MiHA) prior to BM transplantation. Host resistance was sensitively evaluated by colony-forming unit (CFU) assays to directly assess for donor progenitor cell (PC) and peripheral chimerism. B6 host CD8+ T cells but not CD4+ or NK1.1+ cells effected rejection of primitive (CFU-HPP [high-proliferative potential]) and lineage-committed (CFU-IL3/GM [interleukin 3/granulocyte macrophage]) allogeneic donor progenitors. To address complementation by the cytotoxic pathways existing in singly deficient (perforin or FasL) recipients, cytotoxically double (perforin plus FasL) deficient (cdd) recipients were used. Resistance in B6-cdd recipients was comparable to that of wild-type B6 recipients and was also dependent on CD8+ T cells. A “triple” cytotoxic deficient model, involving transplantation of TNFR1−/− (tumor necrosis factor receptor 1) progenitor grafts did not diminish the ability of B6-cdd recipients to reject allografts. Finally, injection of anti-TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) monoclonal antibody (mAb) in B6-cdd recipients also failed to inhibit rejection of TNFR1−/− marrow grafts. In total, these studies demonstrate that CD8+ host T cells can effectively resist MHC-matched MiHA-mismatched donor PCs via alternative effector pathway(s) independent of perforin-, FasL-, TNFR-1–, and TRAIL-dependent cytotoxicity. Therefore, inhibition of these effector pathways in sensitized recipients is unlikely to result in stem cell engraftment following PC allografts.


2016 ◽  
Vol 150 (4) ◽  
pp. S577-S578
Author(s):  
Shivesh Punit ◽  
Philip E. Dubé ◽  
Cambrian Y. Liu ◽  
Nandini Girish ◽  
Kay Washington ◽  
...  

Blood ◽  
2008 ◽  
Vol 111 (6) ◽  
pp. 3116-3125 ◽  
Author(s):  
Cory L. Ahonen ◽  
Anna Wasiuk ◽  
Shinichiro Fuse ◽  
Mary Jo Turk ◽  
Marc S. Ernstoff ◽  
...  

Abstract Identification of Toll-like receptors (TLRs) and their ligands, and tumor necrosis factor–tumor necrosis factor receptor (TNF-TNFR) pairs have provided the first logical, hypothesis-based strategies to molecularly concoct adjuvants to elicit potent cell-mediated immunity via activation of innate and adaptive immunity. However, isolated activation of one immune pathway in the absence of others can be toxic, ineffective, and detrimental to long-term, protective immunity. Effective engineered vaccines must include agents that trigger multiple immunologic pathways. Here, we report that combinatorial use of CD40 and TLR agonists as a cancer vaccine, compared with monotherapy, elicits high frequencies of self-reactive CD8+ T cells, potent tumor-specific CD8+ memory, CD8+ T cells that efficiently infiltrate the tumor-burdened target organ; therapeutic efficacy; heightened ratios of CD8+ T cells to FoxP3+ cells at the tumor site; and reduced hepatotoxicity. These findings provide intelligent strategies for the formulation of multifactorial vaccines to achieve maximal efficacy in cancer vaccine trials in humans.


1997 ◽  
Vol 272 (40) ◽  
pp. 25190-25194 ◽  
Author(s):  
Brian R. Wong ◽  
Jaerang Rho ◽  
Joseph Arron ◽  
Elizabeth Robinson ◽  
Jason Orlinick ◽  
...  

2015 ◽  
Vol 149 (4) ◽  
pp. 993-1005.e2 ◽  
Author(s):  
Shivesh Punit ◽  
Philip E. Dubé ◽  
Cambrian Y. Liu ◽  
Nandini Girish ◽  
M. Kay Washington ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Simona Ronchetti ◽  
Giuseppe Nocentini ◽  
Maria Grazia Petrillo ◽  
Carlo Riccardi

As many members of the tumor necrosis factor receptor superfamily, glucocorticoid-induced TNFR-related gene (GITR) plays multiple roles mostly in the cells of immune system. CD8+T cells are key players in the immunity against viruses and tumors, and GITR has been demonstrated to be an essential molecule for these cells to mount an immune response. The aim of this paper is to focus on GITR function in CD8+cells, paying particular attention to numerous and recent studies that suggest its crucial role in mouse disease models.


2004 ◽  
Vol 200 (2) ◽  
pp. 149-157 ◽  
Author(s):  
Stephanie J. Muriglan ◽  
Teresa Ramirez-Montagut ◽  
Onder Alpdogan ◽  
Thomas W. van Huystee ◽  
Jeffrey M. Eng ◽  
...  

Glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) is a member of the tumor necrosis factor receptor (TNFR) family that is expressed at low levels on unstimulated T cells, B cells, and macrophages. Upon activation, CD4+ and CD8+ T cells up-regulate GITR expression, whereas immunoregulatory T cells constitutively express high levels of GITR. Here, we show that GITR may regulate alloreactive responses during graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT). Using a BMT model with major histocompatibility complex class I and class II disparity, we demonstrate that GITR stimulation in vitro and in vivo enhances alloreactive CD8+CD25− T cell proliferation, whereas it decreases alloreactive CD4+CD25− proliferation. Allo-stimulated CD4+CD25− cells show increased apoptosis upon GITR stimulation that is dependent on the Fas–FasL pathway. Recipients of an allograft containing CD8+CD25− donor T cells had increased GVHD morbidity and mortality in the presence of GITR-activating antibody (Ab). Conversely, recipients of an allograft with CD4+CD25− T cells showed a significant decrease in GVHD when treated with a GITR-activating Ab. Our findings indicate that GITR has opposite effects on the regulation of alloreactive CD4+ and CD8+ T cells.


Sign in / Sign up

Export Citation Format

Share Document